A synthetic peptide for use as a blocking control in assays to test for specificity of AGT antibody, Alternative Names: AGT control peptide, AGT antibody Blocking Peptide, Anti-AGT Blocking Peptide, Angiotensinogen Blocking Peptide, Serpin Peptidase Inhibitor Clade A 8 Blocking Peptide, ANHU Blocking Peptide, SERPINA8 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
AGT
(Angiotensinogen (serpin Peptidase Inhibitor, Clade A, Member 8) (AGT))
Hintergrund
AGT, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease.